Research
Hormonal
The combination of phentermine and topiramate is highly effective for weight reduction, particularly in patients with compulsive overeating or bulimia nervosa, by reducing food intake through central mechanisms.
Phentermine/topiramate is a powerful combination for weight loss, especially for those with binge eating issues. It reduces food intake centrally. It is effective but has significant side effects and contraindications (e.g., glaucoma, hyperthyroidism). It is not approved in Europe due to safety concerns. Use only under strict medical supervision.
GoodSupportsHIGH confidence
Data from available studies indicate significant benefit in weight reduction from this combination in adults with compulsive overeating syndrome or bulimia nervosa. Phntermine/topiramate combination significantly reduced the number of objective binge eating days and period in 28 days surprisingly without a significant effect on the vital signs.
Why this rating
Supported by multiple RCTs.
Source
Pharmacological Support for the Treatment of Obesity—Present and Future
Marcin Kosmalski et al. · Healthcare · 2023
DOI 10.3390/healthcare11030433
narrative_reviewCited 41×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) produce significant weight loss in obese patients (BMI ≥30 or ≥27 with comorbidities) through mechanisms including delayed gastric emptying, increased satiety, and increased resting energy expenditure.Good
- Orlistat reduces body weight by inhibiting gastric and pancreatic lipases, thereby reducing the absorption of dietary fats, with efficacy demonstrated in obese patients.Good
- The combination of bupropion and naltrexone reduces body weight by stimulating POMC neurons to decrease energy intake and increase expenditure, with naltrexone blocking negative feedback to enhance this effect.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →